Goodwin advises life sciences companies across the corporate lifecycle, providing guidance on fundraising, IP portfolio development, regulatory frameworks, and corporate transactions. The firm handles capital markets offerings, licensing and collaboration agreements, M&A transactions, and Hatch-Waxman litigation. Mitchell Bloom and Kingsley Taft serve as global co-chairs of the life sciences practice; both advise emerging through to mature companies on matters including venture financings, strategic alliances, IPOs, and broader corporate affairs. Marishka DeToy focuses on life sciences transactions and represents domestic and foreign issuers and underwriters in a range of offerings. Robert Puopolo regularly advises on IPOs and public offerings, while from Washington, DC Steven Tjoe works with in vitro diagnostic, laboratory developed test, digital health, and non-traditional medical device manufacturers. The recent arrival of Carl Morales from Fenwick & West LLP further strengthens the firm’s life sciences bench in New York. All lawyers mentioned above are based in Boston unless otherwise specified.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Lawyer & team quality
Testimonials
Collated independently by Legal 500 research team.
‘From our experience, Goodwin's IP team has been like our own team and is deeply invested in the success of our company. As compared to other firms, they have more extensive expertise in the subject matter and provide recommendations even if against their own interests.'
'They use technology to further save on costs to client and focus their energy on strategy.’
‘Attentive to Client needs and respectful of Client's perspectives.'
‘Goodwin’s practice was of the highest quality.'
'They recruit lawyers with good business judgement, who bring a level of strategic thought partnership unmatched by other leading firms.'
'They are able to identify for boards what is and is not important to focus on, making legal services efficient and enabling companies to focus their leadership on key strategic matters.’
Key clients
- Dren Bio
- SpringWorks Therapeutics
- Royalty Pharma
- Blueprint Medicines
- Orionis Biosciences
- Zealand Pharma A/C
- Sionna Therapeutics
- Kymera Therapeutics
- Insulet Corporation
- Sandoz, Inc.
- Deep Apple Therapeutics
- IDRx
Work highlights
Advised Blueprint Medicines in its $9.5 billion sale to Sanofi.
Advised Ollin Biosciences on its launch with an initial $100 million in financing.
Advised Sionna Therapeutics on its $219.2 million upsized initial public offering.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Next Generation Partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Practice head
Mitchell Bloom; Kingsley Taft
Other key lawyers
Marishka DeToy; Carl Morales; Robert Puopolo; Steven Tjoe